FDA issued a revised draft guidance on essential drug delivery performance characteristics for devices and combination ...
Kiora Pharmaceuticals licensed ex-Asia rights to KIO-401 (mitucapistat) from Senju for $3.5M upfront. Read how this oral ...
Ascletis' oral GLP-1 ASC30 cut HbA1c by 1.7% in a Phase II type 2 diabetes trial. Read the full results and what they mean ...
Vanda's Nereus (tradipitant) cut semaglutide-induced vomiting to 43% vs 58.5% on placebo in Phase III. Read the full data and ...
UCLA researchers show engineered CAR NK cells selectively kill HIV-infected cells and delay viral rebound after ART stops in ...
SBio's tivunatamig (SSGJ-707) extended median PFS to 13.8 months in Phase II lung cancer. Explore the full ESMO 2026 data and ...
MIT's soft snake-inspired robot crawled 2 meters through pig small intestine in 11 minutes. Read how this early study could ...
Penn Medicine launched the Troiano Brain Tumor Center as part of a USD 35 million initiative to advance brain tumor research and treatment. The center was established through a donation from ...
GSK's Phase III pipeline more than doubles as Cabenuva wins superiority in viremic HIV patients. Read Q3 earnings highlights ...
FDA proposes streamlined approvals for personalized gene editing as CMS expands therapy access model
FDA draft guidance lets sponsors add patient-specific variants to one BLA for personalized genome editing therapies. Read on for CMS access details.
Pelthos Therapeutics (NYSE American: PTHS) agreed to merge with Castle Creek Biosciences, combining Pelthos' commercial dermatology portfolio with Castle Creek's late-stage cell and gene therapy ...
Eli Lilly licensed the SpeechDx speech-biomarker dataset from the Alzheimer's Drug Discovery Foundation to study speech in Alzheimer's research. Read more.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results